Since Acell has failed and seemed a year ago to be “A Cure for Baldness in Five Years” its seems to me that the only 2 research institutes that are really getting substancial funding are Aderans Research and Replicel. Aderans uses a small piece of tissue that is removed from the neckline…”Cells are cultivated in controlled conditions where they are encouraged to multiply by the addition of proprietary growth media. When enough new cells are formed, they are returned to the scalp, where they are injected and elicit new hair growth and thickness, ultimately producing more hair than the client had before.” Replicel has a way to isolate dermal sheath cup cells and cultivate them. They are hopeful that injecting them into the scalp will cause regrowth on the scalp.
Since both Aderans Research and Replicel are in phase 2 of their clinical trials one would think that unless the subjects of the trial were locked in a room for 6 months someone would obviously have come out and said that these injections are working. If so…investors and inside traders wouldn’t flinch to buy Replicel stock (Aderans Research is a private company.) But Replicels stock…regardless of its clinical studies that have been going on for all this time…has a low volume of trade and is at 2.35 a share. With all of this put together…it seems blatantly obvious that besides the procedure being safe…both Replicel and Aderans Research Institute’s attempts at regenerating hair follicles is failing. What is your take on this?
I guess that is one way to look at it. I am unaware of any leaked information, and I’m not even familiar with the ins and outs of these particular trials. I’d have to assume there are non-disclosure or confidentiality agreements which prevent participants from discussing their results (if any). If they are successful, the results will be announced when they’re ready. Rushing things isn’t going to help.
As for looking to insider trading as a sure-fire way to know if a product is coming to market… good luck with that.